Lonza has recently announced three specific investments in the pharma sector in recent weeks. It will build two new customer-dedicated conjugation suites for antibody-drug conjugates (ADCs) at Visp, Switzerland, while adding particle engineering and drug product development at two sites in the US.
Pharmaceutical CDMO Sterling Pharma Solutions has announced a new strategic partnership with ADC Biotechnology, a specialist in antibody-drug conjugates (ADCs). Both companies are UK-based.
Sterling will make an unspecified but significant investment in ADC Bio with a view to acquiring it in Q1 2021, subject to due diligence. The businesses will then work together to develop an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s in high potency small molecules.